NEW YORK (GenomeWeb News) - Accuri Cytometers has netted $5 million in Series B financing from Baird Venture Partners and Arboretum Ventures, the company said today.
Accuri said it will use the money to fund further testing and to propel the full commercial launch of its C6 flow cytometer system.
The C6 system is targeted toward labs that require flow cytometry hardware but lack the funds to buy a high-priced instrument. Accuri plans to market the product for under $30,000.
The company said the system is currently in beta testing.
CEO Jennifer Baird said the funding will "carry Accuri through broader beta testing and position us for full commercial launch next year."
Accuri also said that BVP's Pete Shagory and Arboretum's Tim Peterson have joined its board of directors.